AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31475799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4018
Study 31475799 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4018
Study 30064489 — intervention group
Group type: EXPERIMENTAL
Intervention: SODIS water treatment intervention
Number of subjects: 778
Study 30064489 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual drinking-water sources)
Number of subjects: 778
Study 26658259 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 50
Study 26658259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25526870 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages designed to reduce the frequency of binge drinking through the formation of specific action plans.
Number of subjects: 798
Study 25526870 — intervention group
Group type: COMPARATOR
Intervention: Behaviourally neutral text messages intended to promote retention in the study.
Number of subjects: 798
Study 22578105 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline-enhanced beverage
Number of subjects: 10
Study 22578105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost (0.0015%)
Number of subjects: 27
Study 20700794 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost (0.005%)
Number of subjects: 27
Study 18945637 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 1 mg once or twice daily
Number of subjects: 307
Study 18945637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined levosimendan groups
Number of subjects: 307
Study 18945637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 15716208 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (decompression of the pudendal nerve)
Number of subjects: 32
Study 15716208 — intervention group
Group type: COMPARATOR
Intervention: Control (non-surgical treatment)
Number of subjects: 32
Study 12429622 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2 followed by paclitaxel 200 mg/m2 (1- or 3-hour infusion) for six to seven cycles.
Number of subjects: 82
Study 12429622 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin dose > 360 mg/m2
Number of subjects: 82
Study 12429622 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin dose 420 mg/m2
Number of subjects: 82
Study 12429622 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin dose < or = 360 mg/m2
Number of subjects: 82
Study 10430734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and high doses of budesonide with and without formoterol
Number of subjects: 425
Study 10430734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids prescribed for severe exacerbations
Number of subjects: 425
Study 10430734 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 425
Study 7748095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐operative management with endotracheal intubation, general anesthesia, nasogastric and urinary bladder catheters, position changes, rectal manometer, respiratory pressure module
Number of subjects: 26
Study 7748095 — intervention group
Group type: COMPARATOR
Intervention: Measurement techniques (bladder, rectal, gastric)
Number of subjects: 26
Study 3579494 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25 mg
Number of subjects: 20
Study 3579494 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine 0.1 mg
Number of subjects: 20
Study 3579494 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine 0.5 mg
Number of subjects: 20
Study 3579494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31808183 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment protocol from 2008-2011 (all foals with pulmonary abscesses treated)
Number of subjects: 330
Study 31808183 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment protocol from 2012-2016 (only foals with larger lesions treated)
Number of subjects: 330
Study 31808183 — intervention group
Group type: COMPARATOR
Intervention: Treatment protocol from 2008-2011
Number of subjects: 330
Study 31808183 — intervention group
Group type: COMPARATOR
Intervention: Treatment protocol from 2012-2016
Number of subjects: 330
Study 29288881 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR phenotype screening method
Number of subjects: 0
Study 29288881 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily screening including confirmatory chart reviews
Number of subjects: 0
Study 28747169 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including a two-hour educational session, online video, decision tool, and information booklet.
Number of subjects: 0
Study 28747169 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 0
Study 25703382 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group on 'dealing with disobedience'
Number of subjects: 108
Study 25703382 — intervention group
Group type: COMPARATOR
Intervention: No intervention control
Number of subjects: 108
Study 23312489 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training for 11 weeks
Number of subjects: 49
Study 23312489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 20679559 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 307
Study 20679559 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 307
Study 17997269 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bypass
Number of subjects: 143
Study 17997269 — intervention group
Group type: COMPARATOR
Intervention: Crossover bypass
Number of subjects: 143
Study 17997269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 143
Study 21776461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional advice adapted to a Mediterranean diet (MD)
Number of subjects: 40
Study 16174597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (Maxipime) at 50 mg/kg intravenously twice daily
Number of subjects: 100
Study 16174597 — intervention group
Group type: COMPARATOR
Intervention: Sulbactam/Cefoperazone (Sulperazone) at 50-100 mg/kg intravenously twice daily
Number of subjects: 100
Study 12045314 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational multiple-family group treatment
Number of subjects: 106
Study 12045314 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study 9179369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe lectin-I treatment
Number of subjects: 0
Study 8186809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/day)
Number of subjects: 458
Study 8186809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 3129318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC), 25 mg/day
Number of subjects: 23
Study 3129318 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 tablet/day
Number of subjects: 23
Study 3129318 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 23
Study 11120961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 400 mg
Number of subjects: 0
Study 11120961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg
Number of subjects: 0
Study 11120961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 1600 mg
Number of subjects: 0
Study 11120961 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31476881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 281
Study 31476881 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 281
Study 31476881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Number of subjects: 281
Study 31476881 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Number of subjects: 281
Study 31476881 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP treatment
Number of subjects: 281
Study 29559225 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashing warning light during ERCP
Number of subjects: 200
Study 29559225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no flashing warning light)
Number of subjects: 200
Study 26843544 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPJ resection
Number of subjects: 55
Study 26843544 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPJ fusion
Number of subjects: 55
Study 26843544 — intervention group
Group type: COMPARATOR
Intervention: PIPJ resection and PIPJ fusion
Number of subjects: 55
Study 25102384 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based therapy (ABT) 9h/wk for 24 weeks
Number of subjects: 48
Study 23013404 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-Together intervention (self-directed coping skills intervention including four booklets, a DVD, and a relaxation audio CD)
Number of subjects: 70
Study 23013404 — intervention group
Group type: COMPARATOR
Intervention: Minimal ethical care condition (information booklets from Cancer Council New South Wales and a brochure for the Cancer Council Helpline)
Number of subjects: 70
Study 20357161 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cooling methods (therapeutic hypothermia)
Number of subjects: 481
Study 20357161 — intervention group
Group type: COMPARATOR
Intervention: Standard post-resuscitation care
Number of subjects: 481
Study 17653880 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 508
Study 17653880 — intervention group
Group type: COMPARATOR
Intervention: Serial antenatal monitoring
Number of subjects: 508
Study 15705638 — intervention group
Group type: EXPERIMENTAL
Intervention: Local practice guidelines implemented in hospital B (low grade intervention)
Number of subjects: 1200
Study 15705638 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines reinforced by a clinical pharmacist in hospital C (high grade intervention)
Number of subjects: 1200
Study 15705638 — intervention group
Group type: COMPARATOR
Intervention: No intervention in hospital A (control)
Number of subjects: 1200
Study 12011136 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oophorectomy and tamoxifen (20 mg orally every day for 5 years)
Number of subjects: 709
Study 12011136 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 709
Study 10210974 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (combination of zidovudine, lamivudine, and saquinavir)
Number of subjects: 163
Study 7609287 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition support (feeding tube providing 35 nonprotein kcal/kg of ideal body weight)
Number of subjects: 30
Study 7609287 — intervention group
Group type: COMPARATOR
Intervention: Active Crohn's disease patients (before intervention)
Number of subjects: 30
Study 2575453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 26
Study 2575453 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate with acetaminophen (DPN-A)
Number of subjects: 26
Study 57506 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (CB 154)
Number of subjects: 96
Study 57506 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine 2-5 mg twice daily from the 10th day of the menstrual cycle for 1-11 months
Number of subjects: 96
Study 57506 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine 2-5 mg twice daily for 186 cycles
Number of subjects: 96
Study 57506 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 96
Study 31557329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Number of subjects: 60
Study 31557329 — intervention group
Group type: COMPARATOR
Intervention: Waitlist/Treatment as Usual (WL/TAU)
Number of subjects: 60
Study 31557329 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 28562434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil and 5-Aminolevulinic Acid Photodynamic Therapy (5-FU-ALA-PDT)
Number of subjects: 17
Study 28562434 — intervention group
Group type: COMPARATOR
Intervention: 5-Aminolevulinic Acid Photodynamic Therapy (ALA-PDT)
Number of subjects: 17
Study 25239030 — intervention group
Group type: EXPERIMENTAL
Intervention: US + LLLT
Number of subjects: 45
Study 25239030 — intervention group
Group type: EXPERIMENTAL
Intervention: TE + US + LLLT
Number of subjects: 45
Study 25239030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23784895 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg herbal capsules twice daily
Number of subjects: 60
Study 23784895 — intervention group
Group type: COMPARATOR
Intervention: 400 mg placebo capsules twice daily
Number of subjects: 60
Study 21554496 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐filtration plasmapheresis (DFP)
Number of subjects: 20
Study 19386210 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments used for EM (specific treatments not detailed in the abstract)
Number of subjects: 12
Study 19386210 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 12
Study 16749914 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 3 months
Number of subjects: 32
Study 16749914 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 32
Study 12819167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 50 IU/day
Number of subjects: 30
Study 12819167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10671819 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy
Number of subjects: 0
Study 10671819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclamptic pregnancies
Number of subjects: 0
Study 8872421 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg i.v.) alone
Number of subjects: 57
Study 8872421 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH combined with pyridostigmine (PD) (60 and 120 mg orally at -60 min)
Number of subjects: 57
Study 8872421 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH combined with PD
Number of subjects: 57
Study 8872421 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone or combined with PD in DS adults
Number of subjects: 57
Study 1804283 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU kallikrein t.i.d. for eight days
Number of subjects: 30
Study 1804283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6519623 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide diet
Number of subjects: 0
Study 6519623 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 0
Study 31605983 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy
Number of subjects: 120
Study 31605983 — intervention group
Group type: COMPARATOR
Intervention: Neuroscience group
Number of subjects: 120
Study 31605983 — intervention group
Group type: COMPARATOR
Intervention: Total group
Number of subjects: 120
Study 30278568 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated patch (Lignopad)
Number of subjects: 28
Study 30278568 — intervention group
Group type: COMPARATOR
Intervention: Placebo plasters
Number of subjects: 28
Study 27075659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MNCs (4-μl injections, 1.6 million cells)
Number of subjects: 28
Study 27075659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MNCs (8-μl injections, 3.2 million cells)
Number of subjects: 28
Study 27075659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MNCs (16-μl injections, 6.4 million cells)
Number of subjects: 28
Study 27075659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MNCs (6.4 million cells) plus 30 mg/kg methylprednisolone (MP)
Number of subjects: 28
Study 27075659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MNCs (6.4 million cells) plus MP and a 6-week course of oral lithium carbonate (750 mg/day)
Number of subjects: 28
Study 24892114 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage lateral window sinus lift with simultaneous implant placement
Number of subjects: 60
Study 24892114 — intervention group
Group type: COMPARATOR
Intervention: 2-stage procedure with implant placement delayed by 4 months
Number of subjects: 60
Study 22132792 — intervention group
Group type: COMPARATOR
Intervention: Cold water immersion
Number of subjects: 8
Study 22132792 — intervention group
Group type: COMPARATOR
Intervention: Ice slurry ingestion
Number of subjects: 8
Study 20645948 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 152
Study 20645948 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 152
Study 17653588 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT)
Number of subjects: 68
Study 17653588 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive open thyroidectomy using the Sofferman technique
Number of subjects: 68
Study 15756408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal transsphenoidal endoscopic approach
Number of subjects: 10
Study 15756408 — intervention group
Group type: COMPARATOR
Intervention: Control group (microscopic sublabial transseptal transsphenoidal approach)
Number of subjects: 10
Study 11939990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation via direct laryngoscopy
Number of subjects: 61
Study 11939990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation via an intubating laryngeal mask airway with immediate removal
Number of subjects: 61
Study 11939990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation via an intubating laryngeal mask airway with delayed removal
Number of subjects: 61
Study 11939990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 61
Study 9565250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline treatment (1.5 mg/kg/h)
Number of subjects: 40
Study 9565250 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 7800378 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (30 mg of beta-carotene, 1000 mg of ascorbic acid, and 800 IU of alpha-tocopherol per day for 9 months)
Number of subjects: 79
Study 7800378 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 79
Study 3377462 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg orally twice daily for 4 days)
Number of subjects: 10
Study 3377462 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (200 mg of aminophylline three times daily for 4 days)
Number of subjects: 10
Study 31730832 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) administered before and after treatment of acute exacerbations
Number of subjects: 0
Study 30762744 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic care
Number of subjects: 100
Study 30762744 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 100
Study 28940638 — intervention group
Group type: EXPERIMENTAL
Intervention: l-citrulline (6 g day-1)
Number of subjects: 25
Study 28940638 — intervention group
Group type: COMPARATOR
Intervention: placebo (maltodextrin)
Number of subjects: 25
Study 26342424 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination
Number of subjects: 15459
Study 26342424 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccination with booster dose
Number of subjects: 15459
Study 23610477 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation exercise
Number of subjects: 0
Study 23610477 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 0
Study 23610477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture followed by simulation
Number of subjects: 0
Study 21777095 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic acid (BisBlock) before resin‐based composite (RBC) restorations (n=52)
Number of subjects: 103
Study 21777095 — intervention group
Group type: COMPARATOR
Intervention: Distilled water before RBC restorations (n=51)
Number of subjects: 103
Study 18833582 — intervention group
Group type: EXPERIMENTAL
Intervention: General preoccupation prime
Number of subjects: 60
Study 18833582 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized preoccupation prime
Number of subjects: 60
Study 18833582 — intervention group
Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 60
Study 17198101 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and remifentanil; maintained constant rates to achieve BIS levels of 40-60 during the procedure
Number of subjects: 36
Study 15087795 — intervention group
Group type: COMPARATOR
Intervention: Rigid instrumentation (Group A)
Number of subjects: 45
Study 15087795 — intervention group
Group type: COMPARATOR
Intervention: Semirigid instrumentation (Group B)
Number of subjects: 45
Study 15087795 — intervention group
Group type: COMPARATOR
Intervention: Dynamic instrumentation (Group C)
Number of subjects: 45
Study 11292410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery
Number of subjects: 29
Study 9380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg) via active matrix
Number of subjects: 10
Study 9380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg) via active matrix
Number of subjects: 10
Study 9380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg) via polyptychial matrix
Number of subjects: 10
Study 9380943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg) via polyptychial matrix
Number of subjects: 10
Study 9380943 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 10
Study 8174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 24